348
Views
4
CrossRef citations to date
0
Altmetric
Brief Reports

Renal safety of coformulated tenofovir/emtricitabine vs other nucleoside analogues in combination therapy in antiretroviral-naive patients aged 50 years or older in Spain: The TRIP study

, , , , , , , , , , , , & show all

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Barbara Rossetti, Francesca Montagnani & Andrea De Luca. (2018) Current and emerging two-drug approaches for HIV-1 therapy in ART-naïve and ART-experienced, virologically suppressed patients. Expert Opinion on Pharmacotherapy 19:7, pages 713-738.
Read now

Articles from other publishers (3)

Mariantonietta Pisaturo, Lorenzo Onorato, Antonio Russo, Salvatore Martini, Paolo Chiodini, Simona Signoriello, Paolo Maggi & Nicola Coppola. (2021) Risk of failure in dual therapy versus triple therapy in naïve HIV patients: a systematic review and meta-analysis. Clinical Microbiology and Infection 27:1, pages 28-35.
Crossref
Frederico Duarte & Marcelo A. Soares. (2019) Simplified two-drug antiretroviral HIV treatment. AIDS 33:14, pages 2266-2268.
Crossref
Barbara Rossetti, Roberta Gagliardini, Genny Meini, Gaetana Sterrantino, Vincenzo Colangeli, Maria Carla Re, Alessandra Latini, Manuela Colafigli, Francesca Vignale, Stefano Rusconi, Valeria Micheli, Antonio Di Biagio, Giancarlo Orofino, Valeria Ghisetti, Alessandra Fantauzzi, Vincenzo Vullo, Pierfrancesco Grima, Daniela Francisci, Claudio Mastroianni, Andrea Antinori, Michele Trezzi, Lucia Lisi, Pierluigi Navarra, Benedetta Canovari, Antonella D’Arminio Monforte, Silvia Lamonica, Alessandro D’Avino, Maurizio Zazzi, Simona Di Giambenedetto & Andrea De Luca. (2017) Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial. PLOS ONE 12:11, pages e0187393.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.